Literature DB >> 12941610

Developmental control of Presenilin1 expression, endoproteolysis, and interaction in zebrafish embryos.

Svanhild Nornes1, Casper Groth, Esther Camp, Peter Ey, Michael Lardelli.   

Abstract

Dominant mutations in presenilin1 (PS1) and presenilin2 (PS2) are a major cause of early-onset Alzheimer's disease. In this report we analyze the expression of the zebrafish presenilin1 (Psen1) and presenilin2 (Psen2) proteins during embryogenesis. We demonstrate that Psen1 and Psen2 holoproteins are relatively abundant in zebrafish embryos and are proteolytically processed. Psen1 is maternally expressed, whereas Psen2 is expressed at later stages during development. The Psen1 C-terminal proteolytic fragment (CTF) is present at varying levels during embryogenesis, indicating the existence of developmental control mechanisms regulating its production. We examine the codependency of Psen1 and Psen2 expression during early embryogenesis. Forced overexpression of psen2 increases expression of Psen2 holoprotein, but not the N-terminal fragment (NTF), indicating that levels of Psen2 NTF are strictly controlled. Overexpression of psen2 did not alter levels of Psen1 holoprotein, CTF, or higher molecular weight complexes. Reduction of Psen1 activity in zebrafish embryos produces similar developmental defects to those seen for loss of PS1 activity in knockout mice. The relevance of these results to previous work on presenilin protein regulation and function are discussed. Our work shows that zebrafish embryos are a valid and valuable system in which to study presenilin interactions, regulation, and function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941610     DOI: 10.1016/s0014-4827(03)00257-x

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  12 in total

1.  Characterization of an atypical gamma-secretase complex from hematopoietic origin.

Authors:  Lisa Placanica; Jennifer W Chien; Yue-Ming Li
Journal:  Biochemistry       Date:  2010-04-06       Impact factor: 3.162

Review 2.  Animal models in the drug discovery pipeline for Alzheimer's disease.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

3.  Presenilin-1 Targeted Morpholino Induces Cognitive Deficits, Increased Brain Aβ1-42 and Decreased Synaptic Marker PSD-95 in Zebrafish Larvae.

Authors:  Laura Roesler Nery; Natalia Eltz Silva; Raphaela Fonseca; Monica Ryff Moreira Vianna
Journal:  Neurochem Res       Date:  2017-06-16       Impact factor: 3.996

Review 4.  Zebrafish models in neuropsychopharmacology and CNS drug discovery.

Authors:  Kanza M Khan; Adam D Collier; Darya A Meshalkina; Elana V Kysil; Sergey L Khatsko; Tatyana Kolesnikova; Yury Yu Morzherin; Jason E Warnick; Allan V Kalueff; David J Echevarria
Journal:  Br J Pharmacol       Date:  2017-04-05       Impact factor: 8.739

Review 5.  Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery.

Authors:  Udai Bhan Pandey; Charles D Nichols
Journal:  Pharmacol Rev       Date:  2011-03-17       Impact factor: 25.468

6.  Ubiquilin regulates presenilin endoproteolysis and modulates gamma-secretase components, Pen-2 and nicastrin.

Authors:  Leann K Massey; Alex L Mah; Mervyn J Monteiro
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

7.  Can zebrafish be used as animal model to study Alzheimer's disease?

Authors:  Soraya Santana; Eduardo P Rico; Javier S Burgos
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

8.  SiO2 nanoparticles change colour preference and cause Parkinson's-like behaviour in zebrafish.

Authors:  Xiang Li; Bo Liu; Xin-Le Li; Yi-Xiang Li; Ming-Zhu Sun; Dong-Yan Chen; Xin Zhao; Xi-Zeng Feng
Journal:  Sci Rep       Date:  2014-01-22       Impact factor: 4.379

9.  Zebrafish aplnra functions in epiboly.

Authors:  Svanhild Nornes; Ben Tucker; Michael Lardelli
Journal:  BMC Res Notes       Date:  2009-11-19

10.  Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.

Authors:  Ting Yang; Dilyara Arslanova; Yongli Gu; Corinne Augelli-Szafran; Weiming Xia
Journal:  Mol Brain       Date:  2008-11-04       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.